Yupelri

Chronic Obstructive Pulmonary Disease
Treatment
20 Active Studies for Yupelri

What is Yupelri

RevefenacinThe Generic name of this drug
Treatment SummaryRevefenacin is a type of long-acting muscarinic antagonist (LABA) medicine. It is prescribed for maintenance therapy of chronic obstructive pulmonary disease (COPD) and is the first once-daily nebulized LAMA treatment. Revefenacin was developed by Theravance Biopharma and approved by the FDA in 2018.
Yupelriis the brand name
image of different drug pills on a surface
Yupelri Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Yupelri
Revefenacin
2018
2

Effectiveness

How Yupelri Affects PatientsRevefenacin is a long-acting bronchodilator that has fewer anti-muscarinic side effects. Clinical trials found that it works for a long period of time, and that a single dose of 88 mcg can effectively open up the airways. In tests, patients using Revefenacin were less likely to need rescue inhalers and had increased peak expiratory flow rate that kept increasing until day 7. It was also found to be more selective of the lungs than other LAMAs, leading to fewer sialagogue effects.
How Yupelri works in the bodyRevefenacin is an inhaled medicine that blocks the cholinergic receptors in the airways. It prevents acetylcholine, a chemical messenger, from binding to the receptors, which reduces the muscle contractions of the airways. This helps reduce the severity and frequency of COPD exacerbations. Revefenacin is a long-acting blocker, meaning it only needs to be taken once a day.

When to interrupt dosage

The measure of Yupelri is contingent upon the diagnosed circumstances. The amount of dosage is contingent on the administration strategy (e.g. Solution or Respiratory (inhalation)) outlined in the table beneath.
Condition
Dosage
Administration
Chronic Obstructive Pulmonary Disease
0.175 mg/mL,
Respiratory (inhalation), Solution - Respiratory (inhalation), Solution,

Warnings

Yupelri Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Revefenacin may interact with Pulse Frequency
There are 20 known major drug interactions with Yupelri.
Common Yupelri Drug Interactions
Drug Name
Risk Level
Description
Aclidinium
Major
The risk or severity of adverse effects can be increased when Revefenacin is combined with Aclidinium.
Amitriptyline
Major
The metabolism of Amitriptyline can be decreased when combined with Revefenacin.
Amoxapine
Major
The metabolism of Amoxapine can be decreased when combined with Revefenacin.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Revefenacin.
Cimetropium
Major
The risk or severity of adverse effects can be increased when Revefenacin is combined with Cimetropium.
Yupelri Toxicity & Overdose RiskRevefenacin does not cause the typical side effects associated with anticholinergic medications. Studies have shown that it does not cause cancer, mutate DNA, or affect fertility. Signs and symptoms of overdose include nausea, vomiting, dizziness, feeling faint, blurred vision, increased pressure in the eyes, constipation, and difficulty urinating.
image of a doctor in a lab doing drug, clinical research

Yupelri Novel Uses: Which Conditions Have a Clinical Trial Featuring Yupelri?

At present, 98 studies are actively investigating the potential of Yupelri to ameliorate Chronic Obstructive Pulmonary Disease (COPD).
Condition
Clinical Trials
Trial Phases
Chronic Obstructive Pulmonary Disease
77 Actively Recruiting
Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4

Yupelri Reviews: What are patients saying about Yupelri?

5Patient Review
11/23/2020
Yupelri for Chronic Obstructive Lung Disease
I've been using this medication for close to a year and it's helping. My breathing has gone from 80% two years ago to 90% today, as demonstrated by my most recent test.
5Patient Review
7/23/2019
Yupelri for Chronic Obstructive Lung Disease
This medication has helped me to breathe more easily and with less pressure on my chest. I am able to move more air now, and this drug has been a miracle for my quality of life.
2Patient Review
10/15/2022
Yupelri for Chronic Obstructive Lung Disease
For a while, this medication seemed to help. But after a couple weeks, it stopped having any effect whatsoever. And it's way too expensive for the results (or lack thereof).
2Patient Review
5/7/2019
Yupelri for Chronic Obstructive Lung Disease
Unfortunately, this breathing treatment made my condition worse rather than better. I had to wait for nearly two hours before I could breathe normally again. Needless to say, I won't be using it again and am still on the lookout for a Spiriva alternative.
1Patient Review
11/8/2019
Yupelri for Chronic Obstructive Lung Disease
Unfortunately, my shortness of breath returned less than six hours after taking this medication.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about yupelri

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can Yupelri and albuterol be taken together?

"There is no interaction between albuterol and Yupelri according to current research. However, this does not mean that there is no possibility of an interaction. You should always consult your healthcare provider."

Answered by AI

Is Yupelri a nebulizer?

"Yupelri is a long-term COPD treatment that comes in a vial. Inhale it through your nebulizer once a day to improve your symptoms and help you breathe better."

Answered by AI

What is the drug Yupelri used for?

"YUPELRI is a prescription medicine used to treat chronic obstructive pulmonary disease (COPD). COPD is a long-term (chronic) lung disease that includes chronic bronchitis, emphysema, or both."

Answered by AI

Is Yupelri a steroid?

"Yupelri (revefenacin) is not a steroid. It is a long-acting muscarinic antagonist (LAMA). While steroids lower inflammation (swelling) in the airways of your lungs, Yupelri (revefenacin) opens up your airway passages in your lungs so you can breathe easier."

Answered by AI

Clinical Trials for Yupelri

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+
All Sexes
Stanford, CA
Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.
Waitlist Available
Has No Placebo
Stanford UniversityJeff Swigris, DO, MSMinnesota Health Solutions
Have you considered Yupelri clinical trials? We made a collection of clinical trials featuring Yupelri, we think they might fit your search criteria.Go to Trials
Image of The University of Tennessee Graduate School of Medicine in Knoxville, United States.

Nebulizer vs Inhaler for COPD

18+
All Sexes
Knoxville, TN
The purpose of this study is to compare the effectiveness of inhaled bronchodilators delivered via nebulizers vs. dry powder inhalers (DPIs) in symptomatic participants with Chronic Obstructive Pulmonary Disease (COPD) who have airflow obstruction (FEV1/FVC ≤ 70%) and show significant air trapping (RV ≥ 120% of predicted). The investigators hypothesize that, in patients with symptomatic COPD, therapy with a long-acting anti muscarinic agent/long-acting beta agonist (LAMA/LABA) combination administered by nebulizer will improve hyperinflation (increase in inspiratory capacity and reduction in residual volume) and reduce symptoms related to COPD to a greater extent than LAMA/LABA therapy given by a DPI. The study aims to demonstrate the following: 1. Compare the values of inspiratory capacity (IC) and residual volume (RV) in patients receiving LAMA/LABA by DPI with those receiving LAMA/LABA by nebulizer 2. Compare patient reported outcomes (COPD Assessment Test (CAT score), Baseline/Transition Dyspnea Index (BDI/TDI) and the St. George Respiratory Questionnaire (SGRQ) in symptomatic patients with COPD receiving LAMA/LABA by DPI with those receiving LAMA/LABA by nebulizer
Phase 4
Recruiting
The University of Tennessee Graduate School of MedicineTheravance Biopharma
Have you considered Yupelri clinical trials? We made a collection of clinical trials featuring Yupelri, we think they might fit your search criteria.Go to Trials
Image of University of Massachusetts Chan Medical School in Worcester, United States.

Paramedic Evaluation for Chronic Obstructive Pulmonary Disease

18+
All Sexes
Worcester, MA
Chronic Obstructive Pulmonary Disease (COPD) is a serious lung condition that affects millions of people in the United States. Each year, it leads to about 150,000 deaths, nearly 900,000 emergency room visits, and 700,000 hospital stays. When COPD symptoms suddenly get worse-called an exacerbation-it can seriously harm a person's quality of life and often requires emergency care. Treating these flare-ups early can help prevent hospital visits, but right now, there aren't many good ways to make sure people get care quickly. Mobile Integrated Health (MIH) programs send specially trained paramedics, guided remotely by doctors, to care for patients in their homes. This approach could help people with COPD get faster, more effective care without needing to go to the hospital. In this project, the investigators are testing a new program called PEACE (Paramedic Evaluation for Acute COPD Exacerbation). The PEACE program sends community paramedics to patients' homes-when needed and in partnership with their regular doctors-to manage worsening COPD symptoms early. The study team will adapt the PEACE program to meet the needs of adults living at home with moderate to severe COPD, gather feedback from patients and healthcare providers, and run a small pilot study to see if the program is practical and helpful.
Recruiting
Has No Placebo
University of Massachusetts Chan Medical SchoolLaurel O'Connor, MD, MSc
Image of Cleveland Clinic Foundation in Cleveland, United States.

Multidisciplinary Clinic Evaluation for Sarcopenia Due to COPD

18+
All Sexes
Cleveland, OH
Sarcopenia, or skeletal muscle loss, impacts up to 40% of COPD patients and is a major cause for morbidity and mortality. Despite the high clinical significance of sarcopenia in COPD, the diagnosis remains elusive because accurate measures of skeletal muscle are not tested during routine clinical care. The goal is to use evidence-based strategies to diagnose and treat sarcopenia due to COPD. The multidisciplinary team includes a pulmonologist, pharmacist, COPD nurse, and COPD coordinator. The investigators anticipate that the approach will improve clinical outcomes for COPD patients with sarcopenia as compared to standard of care visits in ambulatory COPD clinics. The investigators will determine if the approach improves skeletal muscle mass and function, and also improves clinical outcomes related to frequency of hospitalization or ED (Emergency Department) visits, COPD exacerbations, and mortality.
Recruiting
Has No Placebo
Cleveland Clinic FoundationAmy Attaway, MD
Image of Duke Asthma Allergy and Airway Center in Durham, United States.

Inhaled Treprostinil for Chronic Obstructive Pulmonary Disease

18+
All Sexes
Durham, NC
The goal of this clinical trial is to evaluate whether inhaled Treprostinil (Tyvaso) can improve oxygen delivery and blood flow in the lungs in adults (age ≥40) with chronic obstructive pulmonary disease (COPD) and hypoxemia who have less severe reduction in lung blood volume (diffusing capacity of the lungs for carbon monoxide \[DLCO\] ≥45%). The main questions it aims to answer are: 1. Does inhaled Treprostinil increase pulmonary capillary blood volume in ventilated lung regions, as measured by hyperpolarized xenon-129 magnetic resonance imaging (HP129Xe MRI)? 2. Does inhaled Treprostinil improve oxygen delivery (measured as red blood cell \[RBC\] chemical shift) and maintain or only slightly change pulmonary vascular resistance (measured by RBC oscillation amplitude)? 3. Can pre-treatment MRI parameters (RBC transfer and RBC oscillation amplitude) predict who will respond to inhaled Treprostinil? Participants will: * Use the Tyvaso nebulizer (inhaled Treprostinil) 4 times daily for 4 weeks, starting at 3 breaths per session and increasing to a maximum of 6 breaths per session as tolerated. * Undergo HP129Xe MRI before and after treatment to assess regional lung function and oxygen exchange. * Complete pulmonary function tests (PFTs), 6-minute walk tests (6MWT), and echocardiograms at the beginning and end of the study. * Be monitored for adverse events, with a phone check-in midway through and after the treatment period.
Phase 2
Recruiting
Duke Asthma Allergy and Airway CenterUnited Therapeutics
Have you considered Yupelri clinical trials? We made a collection of clinical trials featuring Yupelri, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security